Insider Selling: Philip Gregory Sells 15,000 Shares of Sangamo BioSciences Stock (SGMO)
Sangamo BioSciences (NASDAQ:SGMO) VP Philip Gregory sold 15,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.56, for a total transaction of $203,400.00. Following the completion of the sale, the vice president now directly owns 109,347 shares of the company’s stock, valued at approximately $1,482,745. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Sangamo BioSciences (NASDAQ:SGMO) traded down 1.67% during mid-day trading on Friday, hitting $13.56. 430,218 shares of the company’s stock traded hands. Sangamo BioSciences has a one year low of $6.35 and a one year high of $14.60. The stock has a 50-day moving average of $12.42 and a 200-day moving average of $10.56. The company’s market cap is $838.0 million.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.52 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The company’s revenue for the quarter was up 16.3% on a year-over-year basis.
SGMO has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Sangamo BioSciences from $13.00 to $15.00 in a research note to investors on Tuesday, November 5th. They now have an “outperform” rating on the stock. Separately, analysts at Lazard Capital Markets raised their price target on shares of Sangamo BioSciences from $16.00 to $20.00 in a research note to investors on Wednesday, October 23rd. They now have a “buy” rating on the stock. Finally, analysts at Thomson Reuters/Verus upgraded shares of Sangamo BioSciences from a “sell” rating to a “hold” rating in a research note to investors on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Sangamo BioSciences currently has a consensus rating of “Buy” and a consensus price target of $17.58.
Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.